Brad Thompson
Oncolytics Biotech, Inc.
22 Papers
31 Citations
Brad Thompson is an academic researcher from Oncolytics Biotech, Inc.. The author has contributed to research in topics: Reolysin & Medicine. The author has an hindex of 9, co-authored 14 publications. Previous affiliations of Brad Thompson include Cornell University.
Chat about Author
Papers
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies
Eleni M. Karapanagiotou,Victoria Roulstone,Katie Twigger,Mercel Ball,Mary Anne Lagmay Tanay,Christopher M. Nutting,Katie L. Newbold,Martin Gore,James Larkin,Kostas N. Syrigos,Matthew C. Coffey,Brad Thompson,K. Mettinger,Richard G. Vile,Hardev Pandha,Geoffrey D. Hall,Alan Melcher,John D. Chester,Kevin J. Harrington +18 more
TL;DR: The combination of RT3D plus carboplatin/paclitaxel is well tolerated with evidence of activity in cancer of the head and neck and a randomized phase III study is currently open for recruitment.
192
Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.
Wen Qing Yang,Xueqing Lun,Cheryl A. Palmer,M. Elizabeth Wilcox,Huong Muzik,Zhong Qiao Shi,Richard H. Dyck,Matthew C. Coffey,Brad Thompson,Mark G. Hamilton,Sandra Nishikawa,Penny M. A. Brasher,Kevin Fonseca,David George,N. Berry Rewcastle,Randal N. Johnston,D A Stewart,Patrick W.K. Lee,Donna L. Senger,Peter A. Forsyth +19 more
TL;DR: These data show the efficacy and safety of reovirus when it is used in the treatment of gliomas in immunocompetent hosts, and inoculation ofReovirus into the brain of nonhuman primates did not produce significant toxicities.
80
Evaluation of homogeneity and genetic stability of REOLYSIN ® (pelareorep) by complete genome sequencing of reovirus after large scale production
Romit Chakrabarty,Hue Tran,Yves Fortin,Zhenbao Yu,Shi-Hsiang Shen,J L Kolman,David Onions,Robert Voyer,Allison Hagerman,Sarah Serl,Amine Kamen,Brad Thompson,Matthew C. Coffey +12 more
TL;DR: The results obtained from MPS and Sanger sequencing were comparable to those from SS; both demonstrate a high level of homogeneity at the amino acid level and genetic stability of REOLYSIN®.
12
Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.
Romit Chakrabarty,Hue Tran,Iohann Boulay,Tanya Moran,Audrey Parenteau,Robert Tavcar,Maude Bigras,Allison Hagerman,Sarah Serl,Brad Thompson,Matthew C. Coffey +10 more
TL;DR: The purpose of this study was to elucidate the bio-distribution pattern of Reolysin® in healthy Sprague-Dawley rats, and to aid in the design of additional exploratory clinical trials for ReolySin®.
10
Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep.
Amira D Rghei,Laura P. van Lieshout,Wenguang Cao,Shihua He,Kevin Tierney,Jordyn A Lopes,Nicole Zielinska,Enzo M. Baracuhy,Elena S B Campbell,Jessica A. Minott,Matthew M. Guilleman,Pamela C Hasson,Brad Thompson,Khalil Karimi,Byram W. Bridle,Leonardo Susta,Xiangguo Qiu,Logan Banadyga,Sarah K. Wootton +18 more
TL;DR: AAV-mAb expression is a viable method for prolonging the therapeutic effect of recombinant mAbs and represents a potential alternative "vaccine" strategy for those with compromised immune systems or in possible outbreak response scenarios.
10